Burden of Phlebotomy in Patients with Polycythemia Vera in the United States: Baseline Data from the REVEAL Study
Ralph V. Boccia(Center for Cancer and Blood Disorders), Alison R. Moliterno(Johns Hopkins University), Shreekant Parasuraman(Incyte (United States)), Ruben A. Mesa(Atrium Health Wake Forest Baptist), Brady L. Stein(Barnes-Jewish Hospital), Joseph A. Cordaro(Incyte (United States)), Wei Peng(Incyte (United States)), Ahmad Naim(Incyte (United States)), Haowei Sun(University of Alberta)
Cited by 11
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs
|Journal of Clinical Oncology|2012|461
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
|New England Journal of Medicine|2010|425